{"id":"two-cycles-of-neoadjuvant-chemotherapy","safety":{"commonSideEffects":[{"rate":"20-50%","effect":"Nausea"},{"rate":"30-60%","effect":"Fatigue"},{"rate":"50-80%","effect":"Hair loss"},{"rate":"10-30%","effect":"Anemia"},{"rate":"5-20%","effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Neoadjuvant chemotherapy is administered before the main treatment, such as surgery, to reduce the size of the tumor. This approach can make the subsequent treatment more effective.","oneSentence":"Chemotherapy involves the use of drugs to kill rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:37.052Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer"},{"name":"Lung cancer"}]},"trialDetails":[{"nctId":"NCT03387553","phase":"EARLY_PHASE1","title":"HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-06-06","conditions":"Breast Cancer, Breast Cancer Female, Breast Cancer, Male","enrollment":31},{"nctId":"NCT07487662","phase":"PHASE2","title":"TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-18","conditions":"Hepato Cellular Carcinoma (HCC)","enrollment":105},{"nctId":"NCT07407140","phase":"PHASE3","title":"VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-30","conditions":"AML, Adult","enrollment":300},{"nctId":"NCT05825066","phase":"PHASE2","title":"Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2023-08-01","conditions":"Pancreas Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma","enrollment":64},{"nctId":"NCT05108870","phase":"PHASE1, PHASE2","title":"TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-07-17","conditions":"Human Papilloma Virus, HPV, HPV Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":98},{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT05402930","phase":"NA","title":"Angiomammography and Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"CHU de Quebec-Universite Laval","startDate":"2018-01-03","conditions":"Breast Neoplasms","enrollment":67},{"nctId":"NCT02818920","phase":"PHASE2","title":"Neoadjuvant Pembrolizumab","status":"COMPLETED","sponsor":"Neal Ready MD PhD","startDate":"2017-01","conditions":"Non-small Cell Lung Carcinoma","enrollment":35},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT04683315","phase":"PHASE2","title":"PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-04-01","conditions":"Pancreatic Cancer","enrollment":84},{"nctId":"NCT07448142","phase":"PHASE2","title":"Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-15","conditions":"Colorectal Cancer (CRC)","enrollment":50},{"nctId":"NCT04215731","phase":"PHASE3","title":"Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-03-27","conditions":"Rectal Cancer","enrollment":582},{"nctId":"NCT07447570","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-10-15","conditions":"Head and Neck Cancer, Radiotherapy, Anti-PD-1/CTLA-4 Antibody","enrollment":27},{"nctId":"NCT05888402","phase":"PHASE2","title":"Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-01-20","conditions":"Local Advanced Non-small Cell Lung Cancer","enrollment":50},{"nctId":"NCT07033819","phase":"PHASE2","title":"Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-06-25","conditions":"Ovarian Cancer","enrollment":48},{"nctId":"NCT07430579","phase":"NA","title":"Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"The Second Hospital of Shandong University","startDate":"2024-12-09","conditions":"Pathological Complete Remission, Objective Response Rate, Immune-related Adverse Events","enrollment":25},{"nctId":"NCT03174275","phase":"PHASE2","title":"Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2017-12-19","conditions":"Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer","enrollment":39},{"nctId":"NCT07423078","phase":"PHASE2","title":"Window of Opportunity in Preserving Laryngeal Function Trial","status":"NOT_YET_RECRUITING","sponsor":"Matthew Spector","startDate":"2026-03-31","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma","enrollment":87},{"nctId":"NCT04024462","phase":"PHASE3","title":"A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-02-05","conditions":"HER2-positive Early Breast Cancer","enrollment":200},{"nctId":"NCT00003042","phase":"PHASE2","title":"Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"1997-05-30","conditions":"Breast Cancer","enrollment":41},{"nctId":"NCT03407144","phase":"PHASE2","title":"Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-04-09","conditions":"Hodgkin Lymphoma","enrollment":340},{"nctId":"NCT03520491","phase":"PHASE2","title":"A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-04-25","conditions":"Bladder Cancer","enrollment":52},{"nctId":"NCT06348134","phase":"PHASE2","title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer","enrollment":74},{"nctId":"NCT06384560","phase":"PHASE1, PHASE2","title":"Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2024-09-23","conditions":"Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma","enrollment":66},{"nctId":"NCT07402538","phase":"PHASE3","title":"Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-24","conditions":"Oral Cancer, Oropharyngeal Cancer","enrollment":184},{"nctId":"NCT07082179","phase":"PHASE2","title":"A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2025-09-04","conditions":"NSCLC","enrollment":33},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT03727880","phase":"PHASE2","title":"Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Lei Zheng","startDate":"2019-06-04","conditions":"Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma","enrollment":28},{"nctId":"NCT07381543","phase":"PHASE2","title":"Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-03","conditions":"Localized Small Cell Lung Cancer","enrollment":76},{"nctId":"NCT07385664","phase":"PHASE2","title":"Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC","status":"NOT_YET_RECRUITING","sponsor":"Ji Yongling","startDate":"2026-01-28","conditions":"Resectable Esophageal Cancer","enrollment":66},{"nctId":"NCT05621707","phase":"PHASE2","title":"Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2022-11-02","conditions":"Esophageal Squamous Cell Carcinomas, Concurrent Chemoradiotherapy, Immunotherapy","enrollment":50},{"nctId":"NCT07378306","phase":"PHASE2","title":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT04430894","phase":"PHASE2","title":"KRDI in Transplant-Eligible MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-07-10","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT05925530","phase":"PHASE2","title":"Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-02-22","conditions":"Non-small Cell Lung Cancer","enrollment":142},{"nctId":"NCT06739252","phase":"PHASE2","title":"Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA","status":"TERMINATED","sponsor":"Peking University","startDate":"2024-12-31","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Perihilar Cholangiocarcinoma","enrollment":1},{"nctId":"NCT05366166","phase":"PHASE2","title":"Pembrolizumab Plus Olaparib in LA-HNSCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2022-09-02","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":45},{"nctId":"NCT07371897","phase":"PHASE3","title":"Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-06-30","conditions":"Head and Neck Squamous Cell Carcinoma HNSCC","enrollment":154},{"nctId":"NCT07365592","phase":"PHASE1, PHASE2","title":"Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-01","conditions":"Colorectal Cancer","enrollment":138},{"nctId":"NCT07320508","phase":"PHASE2","title":"Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2026-01-20","conditions":"Adenoid Cystic Carcinoma, Sinonasal Carcinoma, Epirubicin","enrollment":100},{"nctId":"NCT06648889","phase":"PHASE2","title":"Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Goethe University","startDate":"2024-10-22","conditions":"T-ALL","enrollment":40},{"nctId":"NCT04229459","phase":"PHASE2","title":"Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baruch Brenner","startDate":"2020-02-16","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":12},{"nctId":"NCT04770272","phase":"PHASE2","title":"Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy","status":"TERMINATED","sponsor":"Palleos Healthcare GmbH","startDate":"2021-03-01","conditions":"Triple-negative Breast Cancer","enrollment":442},{"nctId":"NCT07323056","phase":"PHASE2","title":"Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2026-01-01","conditions":"EGFR-mutant Non-small Cell Lung Cancer, Potentially Resectable","enrollment":36},{"nctId":"NCT07317609","phase":"PHASE1","title":"Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-07-15","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":60},{"nctId":"NCT05249959","phase":"PHASE2","title":"Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2022-03-21","conditions":"Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma","enrollment":49},{"nctId":"NCT03921684","phase":"PHASE2","title":"Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baruch Brenner","startDate":"2019-04-10","conditions":"Rectal Cancer","enrollment":29},{"nctId":"NCT07281157","phase":"PHASE2","title":"Irinotecan Liposome Plus Capecitabine and Enronsubemab Combined With Short-course Radiotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-11-01","conditions":"Advanced Colorectal Cancer","enrollment":30},{"nctId":"NCT05860296","phase":"PHASE1, PHASE2","title":"Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers","status":"TERMINATED","sponsor":"SignalChem Lifesciences Corporation","startDate":"2023-05-31","conditions":"Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic","enrollment":36},{"nctId":"NCT07292142","phase":"PHASE1, PHASE2","title":"FMT in Triple Negative Breast Cancer Guided by ctDNA","status":"NOT_YET_RECRUITING","sponsor":"Jewish General Hospital","startDate":"2026-02","conditions":"Breast Cancer","enrollment":125},{"nctId":"NCT07291401","phase":"PHASE2","title":"Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC","status":"NOT_YET_RECRUITING","sponsor":"Zhongnan Hospital","startDate":"2026-01-01","conditions":"Rectal Cancer Patients","enrollment":108},{"nctId":"NCT05171166","phase":"PHASE2, PHASE3","title":"Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.","status":"TERMINATED","sponsor":"Peking University","startDate":"2021-12-24","conditions":"Hepatocellular Carcinoma","enrollment":18},{"nctId":"NCT07269691","phase":"PHASE3","title":"RaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early/Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Pengfei Qiu","startDate":"2025-12-01","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer","enrollment":194},{"nctId":"NCT06817525","phase":"PHASE2","title":"Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-11-06","conditions":"Triple-negative Breast Cancer","enrollment":64},{"nctId":"NCT07266493","phase":"PHASE2","title":"Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2023-12-01","conditions":"Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy","enrollment":26},{"nctId":"NCT06402864","phase":"PHASE3","title":"Evaluation Contact X-ray Brachytherapy for Rectal Preservation in Intermediate Substage Rectal Adenocarcinoma","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2024-03-26","conditions":"Adult With Intermediate Low or Mid Rectal Adenocarcinoma","enrollment":212},{"nctId":"NCT04224948","phase":"NA","title":"The PET- Retroperitoneal Sarcoma Study","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2020-01-03","conditions":"Retroperitoneal Sarcoma","enrollment":18},{"nctId":"NCT07257575","phase":"PHASE2","title":"A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2025-01-05","conditions":"Gastric Cancer Stage III","enrollment":138},{"nctId":"NCT06576973","phase":"PHASE2","title":"Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-08-08","conditions":"Esophageal Squamous Cell Carcinoma, Neoadjuvant Treatment","enrollment":35},{"nctId":"NCT05659251","phase":"PHASE2","title":"Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-12-01","conditions":"Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy","enrollment":48},{"nctId":"NCT07244978","phase":"PHASE2","title":"Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-12-01","conditions":"Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy","enrollment":49},{"nctId":"NCT06154538","phase":"PHASE2","title":"Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-11-01","conditions":"Locally Advanced Colorectal Carcinoma","enrollment":170},{"nctId":"NCT07248020","phase":"PHASE2","title":"A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational Analysis of Tumor Tissue","status":"NOT_YET_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2026-01-01","conditions":"Rectal Cancer, Locally Advanced Rectal Cancer, Radiation-Induced Enteritis","enrollment":72},{"nctId":"NCT07244965","phase":"PHASE2","title":"Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2025-12-01","conditions":"LOCALLY ADVANCED CERVICAL CANCERS","enrollment":42},{"nctId":"NCT05088395","phase":"NA","title":"Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2022-05-19","conditions":"Cancer","enrollment":2050},{"nctId":"NCT05189730","phase":"PHASE2","title":"Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2021-07-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":80},{"nctId":"NCT07163910","phase":"PHASE2","title":"Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study","status":"RECRUITING","sponsor":"baotai Liang","startDate":"2025-04-20","conditions":"Prostate Cancer","enrollment":93},{"nctId":"NCT07086469","phase":"PHASE2","title":"Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-07-20","conditions":"Toripalimab, Surufatinib, Neoadjuvant Immunochemotherapy","enrollment":69},{"nctId":"NCT06912074","phase":"PHASE2","title":"Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-05","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":134},{"nctId":"NCT07222657","phase":"PHASE2","title":"Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-11","conditions":"Esophageal Adenocarcinoma, Esophageal Cancer","enrollment":40},{"nctId":"NCT01270724","phase":"PHASE2","title":"Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2010-08","conditions":"CNS Germ Cell Tumor","enrollment":10},{"nctId":"NCT04230109","phase":"PHASE2","title":"Sacituzumab Govitecan In TNBC","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-07-14","conditions":"Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer","enrollment":260},{"nctId":"NCT07206810","phase":"","title":"A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2018-08-01","conditions":"Myeloma","enrollment":419},{"nctId":"NCT06467799","phase":"PHASE2","title":"Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-09-01","conditions":"Hepatocellular Carcinoma, Beyond Milan Criteria","enrollment":39},{"nctId":"NCT06124378","phase":"PHASE2","title":"Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2023-11-13","conditions":"Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors","enrollment":60},{"nctId":"NCT03283384","phase":"PHASE2","title":"Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Borstkanker Onderzoek Groep","startDate":"2019-06-15","conditions":"Breast Neoplasms","enrollment":100},{"nctId":"NCT07161115","phase":"PHASE2","title":"Involve-site Radiotherapy Combined With Chemotherapy and Immunotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Longhao Li","startDate":"2025-09-19","conditions":"Rectal Adenocarcinoma","enrollment":60},{"nctId":"NCT04335669","phase":"PHASE3","title":"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lund University Hospital","startDate":"2019-12-20","conditions":"Breast Cancer, Triple Negative Breast Neoplasms","enrollment":325},{"nctId":"NCT04162015","phase":"PHASE1","title":"A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-11-12","conditions":"Malignant Pleural Mesothelioma","enrollment":22},{"nctId":"NCT07055399","phase":"PHASE2","title":"Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)","status":"RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-08-21","conditions":"Locally Advanced Cervical Cancer","enrollment":43},{"nctId":"NCT06770270","phase":"PHASE2","title":"Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-08-01","conditions":"Rectal Cancer","enrollment":68},{"nctId":"NCT05058404","phase":"PHASE3","title":"Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2021-12-01","conditions":"Follicular Lymphoma","enrollment":605},{"nctId":"NCT06509568","phase":"PHASE2","title":"Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-08-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":92},{"nctId":"NCT07137858","phase":"PHASE2","title":"Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-15","conditions":"Oral Squamous Cell Carcinoma (OSCC), Neoadjuvant Chemoimmunotherapy","enrollment":70},{"nctId":"NCT07084610","phase":"PHASE2","title":"Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Hospital das Clínicas de Ribeirão Preto","startDate":"2025-02-25","conditions":"Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07132008","phase":"PHASE3","title":"Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2025-10-01","conditions":"Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors","enrollment":94},{"nctId":"NCT06874933","phase":"PHASE2","title":"Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-05-04","conditions":"HR+/HER2- Breast Cancer","enrollment":35},{"nctId":"NCT05265208","phase":"PHASE2","title":"Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer","status":"RECRUITING","sponsor":"Center Eugene Marquis","startDate":"2022-02-04","conditions":"Resectable Intrahepatic Cholangiocarcinoma","enrollment":62},{"nctId":"NCT06930105","phase":"PHASE2","title":"Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL","status":"NOT_YET_RECRUITING","sponsor":"Xianmin Song, MD","startDate":"2025-09-01","conditions":"Acute Lymphoid Leukemia (ALL)","enrollment":45},{"nctId":"NCT05182385","phase":"PHASE1, PHASE2","title":"Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Goethe University","startDate":"2021-12-15","conditions":"ALL, Recurrent, Adult","enrollment":30},{"nctId":"NCT05275777","phase":"PHASE1, PHASE2","title":"A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2022-05-19","conditions":"HER2-negative Breast Cancer, Advanced Solid Tumor","enrollment":66},{"nctId":"NCT07085234","phase":"PHASE2","title":"Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2025-07-30","conditions":"Locally Advanced Nasopharyngeal Carcinoma, Immunotherapy, Induction Therapy","enrollment":30},{"nctId":"NCT06358573","phase":"PHASE2","title":"Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK","status":"RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2024-10-24","conditions":"Triple-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer","enrollment":54},{"nctId":"NCT06902272","phase":"PHASE2","title":"ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-06-11","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT03547999","phase":"PHASE2","title":"A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC","status":"TERMINATED","sponsor":"Patrick Boland","startDate":"2018-06-26","conditions":"Metastatic Colorectal Cancer","enrollment":17},{"nctId":"NCT06275737","phase":"NA","title":"POP-UP: a Single-arm, Two-cohort Study: Trimodal Prehab for Upper GI and Pancreatic Cancer","status":"RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2024-06-24","conditions":"Pancreatic Ductal Adenocarcinoma, Esophageal Cancer","enrollment":72},{"nctId":"NCT07070622","phase":"PHASE3","title":"Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR)","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-11-01","conditions":"Rectal Cancer","enrollment":186},{"nctId":"NCT06918002","phase":"PHASE3","title":"Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients","status":"RECRUITING","sponsor":"Intergroupe Francophone du Myelome","startDate":"2025-07-09","conditions":"Multiple Myeloma, Newly Diagnosed","enrollment":824},{"nctId":"NCT02845323","phase":"PHASE2","title":"Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-05-16","conditions":"Urothelial Carcinoma, Bladder Cancer","enrollment":15},{"nctId":"NCT04922853","phase":"PHASE3","title":"Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"West China Hospital","startDate":"2021-08-26","conditions":"Rectal Cancer, Neoadjuvant Chemotherapy","enrollment":554},{"nctId":"NCT07055841","phase":"PHASE2","title":"Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Xiuping Ding","startDate":"2023-04-01","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":69}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["paclitaxel and carboplatin"],"phase":"phase_3","status":"active","brandName":"Two cycles of neoadjuvant chemotherapy","genericName":"Two cycles of neoadjuvant chemotherapy","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Chemotherapy involves the use of drugs to kill rapidly dividing cancer cells. Used for Breast cancer, Lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}